KLK3 and bone metastasis: Adopting a PSA cut-off of 18.95 ng/mL can exclude 20% of patients from unnecessary bone scans while missing only 2.5% of bone metastasis, translating into 170 USD of financial savings per client and 55,354 USD of national savings per annum.